Market Assessment, Fragile X Syndrome Executive Insights Fragile X Syndrome Executive Insights US/EU5/China Report

Fragile X Syndrome - Executive Insights - Fragile X Syndrome | Executive Insights | US/EU5/China
- Fragile X Syndrome | Executive Insights | US/EU5/China | 2021

Kristine Mackin, Ph.D.

Kristine Mackin, Ph.D., is a director on the Immune and Inflammatory Disorders team at Clarivate. Her expertise includes emerging microbiome-based therapies, psoriatic arthritis, chronic obstructive pulmonary disease, and asthma. Previously, Dr. Mackin was involved with a new company pitch focusing on the infant microbiome, now realized as Commense, during an internship at Puretech Ventures in Boston. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins.

Buy report Login to access report

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Fragile X Syndrome – Executive Insights – Fragile X Syndrome | Executive Insights | US/EU5/China

Table of contents

Related Market Assessment Reports

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)